What You Will Learn
- Answers to the questions patients and families most commonly ask
- How to evaluate claims about electrical stimulation devices
- Why some clinicians may not have heard of this treatment
This chapter addresses the questions you are most likely to have, or that your family, friends, or clinicians may raise. We have tried to answer them plainly, acknowledging both what the evidence shows and what it does not yet tell us.
"Does this actually work?"
It works. The evidence reviewed in Chapter 5 demonstrates genuine structural restoration of denervated muscle, confirmed by muscle biopsies, CT imaging, and electron microscopy, which gives the most detailed view of tissue structure available. This is not speculation or anecdote. It is peer-reviewed science published in reputable journals and now being replicated by research groups working independently of the original programme.
Chapter 3 traced the long history of dubious electrical claims, from Aldini's demonstrations to today's consumer devices with exaggerated marketing. But the science behind denervated muscle stimulation is as well-established as any in rehabilitation medicine. The treatment parameters are derived from measurable biophysical properties of the tissue, and the outcomes are documented with a depth of structural evidence rarely seen in rehabilitation research.
"Why hasn't my clinician heard of this?"
This is, unfortunately, common. Research has identified that the primary barrier to adoption is not patient resistance but clinician confidence and knowledge. Many physiotherapy and rehabilitation training programmes do not cover denervated muscle stimulation (or even more general applications of electrical stimulation). The specialist equipment is different from the devices most clinicians are familiar with. And the persistent association of electrotherapy with quackery (discussed in Chapter 3) means that some healthcare professionals approach the entire field with more scepticism than the evidence warrants.
If your clinician has not heard of this treatment, that does not mean it is ineffective. It means the gap between evidence and practice, which is common across many areas of medicine, has not yet been closed in your clinical team.
"What about the negative trial I read about?"
There is one sham-controlled randomised trial in this field (Piccinini and colleagues, 2020) that found no significant benefit. In that study, 38 people with nerve injuries each had two affected muscles: one muscle was given real stimulation and the other sham stimulation, three times a week for 36 sessions. Everyone improved, and the stimulated muscles did no better than the sham-treated ones. This deserves a plain discussion.
The Piccinini trial studied patients with recent peripheral nerve injuries where some natural recovery was expected. This is a fundamentally different situation from the RISE population, who had long-standing, permanent denervation with no prospect of recovery. In recent injuries, any treatment effect must be detected against a background of natural recovery, which is a much harder statistical challenge. The stimulation settings and duration also differed from the RISE protocol: 36 sessions over a few months, rather than five days a week for two years with a progression from twitch to tetanic training. The trial's own investigators acknowledged that the study design may not have been optimised to detect a treatment effect.
The best interpretation is this: the Piccinini trial demonstrates that the conditions under which electrical stimulation benefits denervated muscle may be narrower than sometimes assumed. It does not demonstrate that stimulation is ineffective for the population and protocol studied by the RISE programme. Both findings can be true at the same time.
"Why is most of the evidence from one research group?"
Most of the evidence on denervated muscle comes from the Vienna group and their collaborators. This is a genuine limitation. However, it is important to understand why: the research required specialist equipment, a specific patient population, long treatment timescales, and invasive outcome measures (biopsies). Few research groups have had the combination of funding, expertise, and patient access to replicate this work.
Encouragingly, independent replication is now emerging. The Swiss Paraplegic Centre and a Veterans Affairs medical centre in Richmond, Virginia have both reported positive findings with long-pulse stimulation in people with denervated muscle after spinal cord injury, using their own protocols and their own patients, independently of the Vienna programme. At Anatomical Concepts we have now applied these techniques for around 15 years.
"Is it safe?"
Yes, when proper equipment and technique are used. The currents needed for denervated muscle are far higher than those used in ordinary muscle stimulation, and the risk of a skin burn is real if that current is not spread over a large enough electrode. The RISE equipment manages this through large purpose-designed electrodes and a balanced output with no direct-current component, rather than by lowering the current. The RISE publications report no stimulation-related harm in the 25 people treated over two years, though side effects were not something the study set out to measure, and a twelve-month randomised pilot study in the United States described the approach as safe. A systematic review of conventional muscle stimulation in intensive care, covering four randomised trials and 162 patients, identified only one superficial burn, caused by improper settings. In some 15 years of supplying the RISE stimulator we have had no safety issues relating to its use, although that is our experience rather than published evidence.
The safety concern was always about inadequate equipment and technique, not about the principle of the treatment itself. Using standard consumer electrodes (small adhesive pads) with the high currents needed for denervated muscle would indeed be dangerous. Using purpose-designed large electrodes with specialist equipment is safe. This distinction matters.
"Why is the equipment so expensive?"
This is a fair question. Specialist devices cost significantly more than consumer units. The explanation is not profiteering. It reflects three realities:
Engineering requirements. Devices for denervated muscle must incorporate safety systems that consumer products do not need: current-controlled output, balanced waveforms to prevent chemical damage, fault-detection circuits, and electrical isolation. These are mandatory safety features, not optional extras.
Regulatory requirements. Medical devices must meet strict safety and performance standards, undergo independent assessment, and maintain ongoing compliance. For a mass-market product those costs are spread across millions of units. For a specialist device serving a small population they can become prohibitive, and we know of manufacturers who have stopped making electrical stimulation devices for that reason.
Small market. The number of people who need these specialist devices is small compared with the consumer market. Every unit produced carries a proportionally larger share of the development and manufacturing costs.
Chapter 16 explains the regulatory landscape in more detail. The key point is that the cost reflects genuine investment in your safety, not a markup on components.
"Will electrical stimulation interfere with nerve regrowth?"
No. This concern persisted for decades, but the evidence has substantially resolved it. Research has shown that electrical stimulation does not impede nerve regrowth and may actually support it. Brief electrical stimulation applied at the time of nerve surgery has been shown in small clinical trials to improve the number of nerve fibres that reconnect with muscle. One caveat: a 2026 study in rats, after nerve repair, found that stimulating more often (weekly rather than every two weeks) made nerve regeneration worse, so the pattern and dose of stimulation still matter, which is one more reason to follow the programme your clinician sets rather than improvise. You and your clinical team should feel confident that appropriate electrical stimulation will not compromise any potential for nerve recovery.
Chapter Summary
The concerns most commonly raised about electrical stimulation for denervated muscle, effectiveness, safety, cost, the quackery association, and the single-research-group limitation, all have plain, evidence-based answers. The treatment works, as demonstrated by biopsy-confirmed structural restoration. It is safe when proper equipment is used. The cost reflects genuine engineering and regulatory requirements. The evidence base, while concentrated, is being independently replicated. Appropriate electrical stimulation does not interfere with nerve regrowth. The biggest barrier to treatment is not any limitation of the therapy itself but the gap between what the evidence shows and what patients and clinicians are aware of.